KF
PGNX

Krilogy Financial’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Krilogy Financial’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-300
Closed -$2K – 829
2017
Q4 		$2K Hold
300
– – ﹤0.01% 714
2017
Q3 		$2K Buy
+300
New +$1.91K ﹤0.01% 756
2016
Q1 		– Sell
-500
Closed -$3K – 707
2015
Q4 		$3K Hold
500
– – ﹤0.01% 364
2015
Q3 		$3K Buy
+500
New +$3.84K ﹤0.01% 529

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Krilogy Financial's PGNX Position: Q1 2018 in Review

Krilogy Financial sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2018, closing a stake of 300 shares — an estimated $2K sold.

Krilogy Financial first reported a position in PGNX in Q3 2015 and held it in 4 quarters. The position peaked at $3K in Q4 2015. 152 funds tracked by Wall St. Rank hold PGNX as of Q1 2018.

  • Krilogy Financial reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2018 after selling out during the quarter.
  • Krilogy Financial sold 300 Progenics Pharmaceuticals Inc shares in Q1 2018, an estimated $2K.
  • Krilogy Financial first reported a position in Progenics Pharmaceuticals Inc in Q3 2015 and held it in 4 quarters.
  • Krilogy Financial's Progenics Pharmaceuticals Inc position peaked at $3K in Q4 2015.
  • 152 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2018.

Based on Krilogy Financial's 13F filing for Q1 2018, filed 15 May 2018.